Jerry, everyone. Thanks, good afternoon, and
Jerry treatment IFI company, in for implement for As of for much a Matinas. less would the small pathway outlined first-line indications gain MATXXXX feedback very by be mentioned, FDA approval any to the company and to like Matinas challenging
a infection. treatment margin example, of fungal care single indication For given of a XX% would the require a one-to-one invasive in all-cause approximately randomization a against non-inferiority XXX mortality for assuming for patients, standard
simply Matinas feasible and a companies, patients this For cost such large study number the follow such required of treat not for enroll, the believe and is the overall disease a we orphan most of perspective in time an and conducting to from of population.
was the clinically out of compassionate in use forward resistant or in access the a intolerant most options. patients azole with direction seen previously, the as expanded which patients or That azole patients treatment to FDA said, combined limited in with has with This, of used called and MATXXXX Jerry development meaningful MATXXXX our indication be the clear receiving in outcome specifically MATXXXX. provided program, move likely to that mentioned
potentially infections target tissues challenging of severe still numbers a both ability deadly outcomes multiple the are case in and access in expanded different measurable different fairly invasive and MATXXXX and to observed the fungal eradicate effectively clinical most infections multiple small, variety the circumstances. highlights safely target While fungal of in
on provide development few like MATXXXX. B. FDA's orally use first, derive detail cases next feedback targeted a the compassionate patients potential benefit minutes. I'll steps our the from But in form in could to discuss would key message is most to opportunity a of I to regulatory more narrow A our of a our that clinical focus the population safe, of amphotericin administered from the
amphotericin azole-intolerant requiring or attributable such limited are of extended These severe IFIs azole-resistant well options, treatment as fungal or to renal with as treatment with as patients IV-administered patients very toxicity with patients electrolyte life-threating infections. abnormalities
program, feedback we the outcomes positive is the and this best expanded proceed our pathway. clinical Given to in of with seeing action LPAD of are believe continued development MATXXXX the we course under access
the for IFIs fewer overall significantly could treatment approval step-down clinical patients variety with population database options. in targeted treatment to oral patient this an the We treatment require such indications in more of limited a believe obtain of
drugs with streamlined in process. needs. unmet like serious would to details and regulatory treat Food, in briefly Federal the specifically antifungal intended life provide antibacterial I a starting limited pathway Cosmetic LPAD to to and was now Drug the infections describe XXXX to process for This and and late Act of patient around populations added was some the
population. the more patient risk LPAD of for approval is Labeling prevalence drug the available pathway that for or assessment a is considers rarity, particular the alternatives that based conveys under the of and on infection benefit intended lack to flexibly the treat the drugs severity, the
whether is the whether to left or the Determining will matter impact progress judgment condition a but serious severe on will of more based drug an condition, have untreated, from FDA, by likelihood less the as such day-to-day factors is is the on serious that survival, one. condition a a generally if functioning
antibacterial clinical expanded seen these strongly As with received use To-date, FDA pathway. positive the under we've our have LPAD the noted previously, two program. align approval outcomes criteria drugs from
active This for an an available pathway these comparator, alternatives defined designs could including or of us the active lack of a trial comparator therapy, comparator few allow best external either consider many involving prespecified potentially recognizing appropriately to patients. different
be are registration working optimal evaluate now MATXXXX to path LPAD to under accelerated pathway. best to approved position We the forward an
protection eligible drug the exclusivity Fast-Track exclusivities could of in MATXXXX in and continue that FDA under qualify noting designation registration US would possibly review consideration to well. for for the incentives worth also XX under designation the as pathways, LPAD and as remain XX well is years the It breakthrough and priority approval potentially as years QIDP for that orphan allow MATXXXXcould also for EU.
Development We funding the possible MATXXXX with steps also Biomedical Authority, discuss through registration. or as to plan Research for next as engage quickly to and BARDA,
development that believe of most or with strong. addressing to of options, the highest limited MATXXXX that Given our quite BARDA we treatment patients, plan on no is of the case funding we further whom assist alternative have for need
experienced others, and/or program or instituting University not toxicity Michigan, while have Now, Johns Hopkins, turning of azoles ago, physicians who infaterisin classes behalf other significant of to National are to the Institute Nationwide have we of have or Health, about the from Since IV renal received Hospital patients inbound our to Children's antifungals. B among receiving at on responded unable requests tolerate of a expanded access and program. year
infections coccidioidomycosis, infectious have These this aspergillosis, and the additional patients diseases, Pusarion and system, in life-threatening bone, in central To bladder other from the pending. including suffered the date, an eight have involved also rotatorial candida, various several patients infections. tissues body, sinus, with and lung, case skin, enrolled mucormycosis, These brain. including been program fungal nervous different including
with IV longer MATXXXX, months evidence from treatment for expanded program The as significant All range our treatment-limiting treatment with B access or monotherapy turning of kidney administered patients six treatment with to all no to before any weeks toxicity. of experienced two toxicity MATXXXX. renal amphotericin with duration
their nephrotoxicity improvement have eight one MATXXXX. for treatment to Kidney issues. with after function for patients, ongoing four and infatericin and experienced no for returned supplementation. need infection all their unrelated of MATXXXX no as patients any resolution or to successfully MATXXXX intolerance normal with received patient patients Three of treatment initial the IV to who or reasons receive have with further with to infection electrolyte significant safety treatment tolerability the clinical completed an discontinuing Of continue switching have
after and continue to MATXXXX receive Additionally, the from oral soon MATXXXX to basis. treatment hospital their patients outpatient an on all switching discharged with were
X Speaker
comprehensive Disease, States. in or patients use Infectious for the Dr. overall year, at Clinical In which life University another Children's the the Nationwide was a the United one European ECCMID. Ohio, compelling share on Hospital we from hospitals Miceli Microbiology largest of highly each pleased quality case, and and and research reported Marisa most Today, Congress is successful to of case are this Earlier presented of pediatric details as favorable. of in Michigan, recognized institutes at the case of the impact compassionate
MATXXXX girl to and resistant electrolyte from hydration but XX-year-old our enrolling liposomal instance, that infections myeloid species species. of leukemia was required suffered abnormalities remainder multiple lung who and develop IV-amphotericin electrolyte The as toxicity used at this oral and and Access and treat her continue invasive intravenous was underlying In diabetes began supplementation. due discharged core to was hospitalization Program, sinus, with B Upon and home. treated treatment-limiting treatment discontinued, was the as well with patient the initially a for brain hospital renal the IV from Expanded highly MATXXXX treatment acute patient fungal she in B, Aspergillus with amphotericin in new to
repeated new The reduction patient any function a weeks showed in returned stopped Importantly, of renal the showed signs Similarly, chest a invasive patient no MATXXXX. no evidence nodules only MATXXXX. infection. active for following to total improvement sinus MRI have patient There XX evidence nephrotoxicity. three on and clinical began brain lesions. of recurrent no pulmonary weeks fungal show mucormycosis continued no repeated with of with of scan CT for the MATXXXX Her and to infections the since been normal therapy of
This case infections. the use and pediatric first in treating patient deadly represents extremely of an clinical in the highlights these ever potential compromised MATXXXX MATXXXX of
point Song, renal resolved, words in to our and an three to enabling MATXXXX to dysfunction of Rapidly our continue patient's switch be this journey. a Dr. patient intolerance for gastrointestinal Eunkyung the turning additional her treating her proved MATXXXX In therapy the physician, months. decision to
and MATXXXX, invasive Throughout radiologic this improvement of to infections. the imaging period, tolerance revealed the patient displayed excellent fungal subsequent
are challenging patient's remarkable with outcome effectively. addressed We condition achieved this which with delighted MATXXXX, very the
Dr. We of at participation appreciate Matinas the
their Children clinical Nationwide program, with who thus along Song, far. a in have physicians all the and patients program in participated Hospital our development
clinical meaningful Our and trial of interest setting. to And expanded clinical us access MATXXXX continues these as program outside the data most efficacy generate presents program additional increasing demonstrate is attracting to challenging in opportunities additional for this cases.
We treatment patients MATXXXX of where continue the to evaluate requests options. for other compassionate help access use without may
over performance. to the like Keith? to financial to review our turn I'd Keith Kucinski Now call
